Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 6
2004 2
2005 2
2006 4
2007 7
2008 1
2009 2
2010 2
2011 2
2012 3
2013 3
2014 2
2015 2
2016 8
2017 4
2018 8
2019 8
2020 6
2021 5
2022 4
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
The immunosuppressive molecule HLA-G and its clinical implications.
González A, Rebmann V, LeMaoult J, Horn PA, Carosella ED, Alegre E. González A, et al. Among authors: rebmann v. Crit Rev Clin Lab Sci. 2012 May-Jun;49(3):63-84. doi: 10.3109/10408363.2012.677947. Epub 2012 Apr 26. Crit Rev Clin Lab Sci. 2012. PMID: 22537084 Review.
HLA-G expression in malignant melanoma.
Rebmann V, Wagner S, Grosse-Wilde H. Rebmann V, et al. Semin Cancer Biol. 2007 Dec;17(6):422-9. doi: 10.1016/j.semcancer.2007.06.010. Epub 2007 Jun 28. Semin Cancer Biol. 2007. PMID: 17689098 Review.
Elevated sHLA-G plasma levels post chemotherapy combined with ILT-2 rs10416697C allele status of the sHLA-G-related receptor predict poorest disease outcome in early triple-negative breast cancer patients.
Hoffmann O, Wormland S, Bittner AK, Hölzenbein J, Schwich E, Schramm S, Rohn H, Horn PA, Kimmig R, Kasimir-Bauer S, Rebmann V. Hoffmann O, et al. Among authors: rebmann v. Front Immunol. 2023 May 22;14:1188030. doi: 10.3389/fimmu.2023.1188030. eCollection 2023. Front Immunol. 2023. PMID: 37283737 Free PMC article.
Expansion of functional personalized cells with specific transgene combinations.
Lipps C, Klein F, Wahlicht T, Seiffert V, Butueva M, Zauers J, Truschel T, Luckner M, Köster M, MacLeod R, Pezoldt J, Hühn J, Yuan Q, Müller PP, Kempf H, Zweigerdt R, Dittrich-Breiholz O, Pufe T, Beckmann R, Drescher W, Riancho J, Sañudo C, Korff T, Opalka B, Rebmann V, Göthert JR, Alves PM, Ott M, Schucht R, Hauser H, Wirth D, May T. Lipps C, et al. Among authors: rebmann v. Nat Commun. 2018 Mar 8;9(1):994. doi: 10.1038/s41467-018-03408-4. Nat Commun. 2018. PMID: 29520052 Free PMC article.
Peripheral HLA-G/ILT-2 immune checkpoint axis in acute and convalescent COVID-19 patients.
Rohn H, Schramm S, Pansikaki K, Jansen S, Hendriks C, Platte M, Konik MJ, Dolff S, Wilde B, Kordelas L, Trilling M, Krawczyk A, Horn PA, Witzke O, Rebmann V. Rohn H, et al. Among authors: rebmann v. Hum Immunol. 2023 Aug;84(8):393-400. doi: 10.1016/j.humimm.2023.03.002. Epub 2023 Mar 14. Hum Immunol. 2023. PMID: 36925435 Free PMC article.
Tumor-Derived Extracellular Vesicles Impair CD171-Specific CD4+ CAR T Cell Efficacy.
Ali S, Toews K, Schwiebert S, Klaus A, Winkler A, Grunewald L, Oevermann L, Deubzer HE, Tüns A, Jensen MC, Henssen AG, Eggert A, Schulte JH, Schwich E, Rebmann V, Schramm A, Künkele A. Ali S, et al. Among authors: rebmann v. Front Immunol. 2020 Mar 31;11:531. doi: 10.3389/fimmu.2020.00531. eCollection 2020. Front Immunol. 2020. PMID: 32296437 Free PMC article.
79 results